Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685347 · ClinicalTrials.gov registry record · Phase 2
Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects
A Phase 2 study of Asthma and Bronchoconstriction, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 6
- Study locations
NCT00685347: Completed Phase 2 study of Asthma and Bronchoconstriction, sponsored by Sumitomo Pharma America.
NCT00685347 is a Phase 2 study of Asthma and Bronchoconstriction that has completed, run by Sumitomo Pharma America. The registered enrollment target is 33 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00685347, a Phase 2 study of Asthma and Bronchoconstriction, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in pediatric subjects with asthma
Conditions Studied
Interventions
- DRUG Levalbuterol HFA MDI
- DRUG Racemic Albuterol
Study Locations (6)
Colorado
- - Denver
- - Englewood
California
- - Long Beach
Massachusetts
- - Russells Mills
Texas
- - Dallas
Virginia
- - Burke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00685347 record still lists
NCT00685347 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Levalbuterol HFA MDI is the first listed.
NCT00685347 lists 6 locations in 5 states (Colorado, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00685347 about?
NCT00685347 is a clinical study titled "Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects". The purpose of this study is to investigate, using an exercise challenge approach, the dose response of levalbuterol HFA MDI in pediatric subjects with asthma
What is the current status of trial NCT00685347?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2003-01. Estimated completion is 2003-06.
What conditions does trial NCT00685347 study?
This clinical trial studies the following conditions: Asthma, Bronchoconstriction.
What interventions are being tested in trial NCT00685347?
The interventions under investigation include: Levalbuterol HFA MDI (DRUG), Racemic Albuterol (DRUG).
Who is sponsoring clinical trial NCT00685347?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00685347 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00685347's enrollment target sits among peer trials
33 296th of 374 higher than 79 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia